FLAME随机对照试验:标准全前列腺放疗联合或不联合病灶推量的毒性比较
FLAME是一项3期多中心随机对照试验,纳入病理证实的局限性中高危前列腺癌患者,标准组(n=287)接受全前列腺77 Gy/35次,推量组(n=284)在此基础上对多参数MRI定义的前列腺内可见肿瘤行整合推量至95 Gy。结果显示两组2年内≥2级泌尿生殖(GU)和胃肠(GI)毒性相似,提示局部剂量推量未增加毒性。
要点
- 推量组对MRI定义的前列腺内肿瘤整合推量至95 Gy,全前列腺仍为77 Gy/35次。
- 2年内≥2级GU毒性两组相似(OR 1.19,95%CI 0.82-1.73,P=0.38)。
- 2年内≥2级GI毒性两组相似(OR 1.02,95%CI 0.78-1.33,P=0.81)。
核心结论
- 在中高危前列腺癌患者中,整合于标准外照射的局部剂量推量在治疗结束后2年内未较标准治疗增加GU和GI毒性,提示该技术安全可行。
研究设计与样本
- FLAME为3期多中心随机对照试验(NCT01168479),纳入病理证实的局限性中高危前列腺癌患者。
- 标准组(n=287)接受全前列腺77 Gy/35次。
- 推量组(n=284)接受全前列腺77 Gy/35次,并对多参数MRI定义的前列腺内宏观肿瘤整合推量至95 Gy。
- 采用CTCAE 3.0评估治疗相关毒性,通过比例和广义估计方程(GEE)比较2年内≥2级GU或GI事件。
主要发现
- 分析时中位随访55个月。
- GI和GU毒性患病率均至治疗结束时升高、随后回落,组间无明显差异。
- 晚期累积GI毒性率标准组和推量组分别为11.1%和10.2%,GU毒性率分别为22.6%和27.1%。
- GEE分析显示2年内≥2级GU毒性(OR 1.19,95%CI 0.82-1.73,P=0.38)和GI毒性(OR 1.02,95%CI 0.78-1.33,P=0.81)组间相似。
临床怎么用
- 对于中高危局限性前列腺癌,可考虑在标准全前列腺外照射基础上对MRI定义的可见肿瘤行整合推量,而不必担心2年内GU和GI毒性增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. MATERIAL AND METHODS: FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions. The dose-escalated treatment arm (n = 284) received 77 Gy in 35 fractions to the entire prostate, with an integrated boost up to 95 Gy to the multi-parametric MRI-defined (macroscopic) tumour within the prostate. Treatment related toxicity was measured using the CTCAE version 3.0. Grade 2 or worse GU or GI events up to two years were compared between groups by presenting proportions and by Generalized Estimating Equations (GEE) analyses for repeated measures. RESULTS: Ninety percent of the 571 men randomly assigned between September 2009 and January 2015 had high-risk disease (Ash 2000), of whom nearly 66% were prescribed hormonal therapy up to three years. Median follow-up was 55 months at the time of this analysis. Toxicity prevalence rates for both GI and GU increased until the end of treatment and regressed thereafter, with no obvious differences across treatment groups. Late cumulative GI toxicity rates were 11.1% and 10.2% for the standard and dose-escalated group, respectively. These rates were 22.6% and 27.1% for GU toxicity. GEE analyses showed that both GU toxicity and GI toxicity (≥grade 2) up to two years after treatment were similar between arms (OR 1.02 95%CI 0.78-1.33p = 0.81 and (OR 1.19 95%CI 0.82-1.73p = 0.38), respectively. CONCLUSIONS: In intermediate- and high-risk prostate cancer patients, focal dose escalation integrated with standard EBRT did not result in an increase in GU and GI toxicity when compared to the standard treatment up to two years after treatment. This suggests that the described focal dose escalation technique is safe and feasible.
引用
- Monninkhof EM, van Loon JWL, van Vulpen M, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiother Oncol. 2018. PMID: 29336835. doi:10.1016/j.radonc.2017.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。